R1 Therapeutics
PrivateClinical-stage biopharma developing a first-in-class treatment (AP306) for hyperphosphatemia in chronic kidney disease patients. AP306 is a pan-phosphate transporter inhibitor with a Phase 2b study planned for 2026.
Founders Peter Thomson
CEO Peter Thomson
Company
Founded
2025
Headquarters
San Francisco, United States
Financials
Total Funding
$78M
Sectors
Funding History
1 round Series A Mar 17, 2026
$78M Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.